Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20743744 | 0.87 | NPC1 (0.46) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20743828 | 0.85 | NPC1 (0.43) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20762573 | 0.85 | NPC1 (0.45) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20743792 | 0.85 | NPC1 (0.45) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20743807 | 0.85 | NPC1 (0.45) | NPC1PSEN1PSEN2APH1BNCSTN | |
| Alpibectir SCHEMBL20743785 | 0.85 | NPC1 (0.45) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20744263 | 0.84 | NPC1 (0.42) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20743880 | 0.84 | NPC1 (0.44) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20743798 | 0.82 | NPC1 (0.41) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15837679 | 0.82 | NPC1 (0.43) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997680-B | Novel compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-10-21 | — | — | CN | claimed |
| US-11254689-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| EP-3668879-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | claimed |
| US-20210032268-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-04 | — | — | US | claimed |
| EP-3668879-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | claimed |
| WO-2019034700-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | claimed |
| CN-110997680-B | Novel compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11254689-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | disclosed |
| EP-3668879-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| EP-3668879-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20210032268-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-04 | — | — | US | disclosed |
| EP-3668879-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034700-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034700-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032268-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | NPC1 88/4885PSEN1 2688/4885PSEN2 3190/4885 |
| US-11254689-B2 | Compounds | SDHA, SDHB, FDPS | NPC1 114/4885PSEN1 1986/4885PSEN2 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.